FOXO4-DRI dosing & administration
A senolytic peptide that clears aged "zombie" cells to support healthy aging — run in short, cycled courses a few times a year.
Written by Michael Carroll — Owner, Director of Research · Reviewed by the Peptide Initiative Research Team · Editorial standards
Dosing
How much FOXO4-DRI do I take?
Timing
Best time to take
Morning is most common. Because FOXO4-DRI is cycled in short bursts rather than taken daily, exact time of day matters less than sticking to your every-other-day or 5-on/2-off schedule.
With food?
Food does not matter — it is injected under the skin, not swallowed, so it works the same whether you have eaten or not.
If stacking
Run FOXO4-DRI as its own short cycle. Many people pair senolytic cycles with healthy-aging basics like NAD+ precursors, spermidine, or fisetin between cycles, but keep other senolytics out of the same cycle so you can judge how you respond.
Adjusting your dose
Increase if
- You tolerated a starting cycle well with no strong reaction
- You have higher body weight and are moving toward the weight-based protocol
- Your goal is clearing a heavier senescent-cell burden
Decrease if
- You feel notably run-down, flu-like, or fatigued during a cycle
- You get strong injection-site reactions
- You are new to senolytics and want to ease in
Signs of right dose
- You get through a cycle with only mild, short-lived fatigue
- Improved energy, recovery, or skin quality in the weeks after a cycle
- No lingering side effects between cycles
Administration
How do I use FOXO4-DRI?
Reconstitution
What you need
Injection
Route
Subcutaneous — a small injection into the fat just under the skin, using an insulin syringe.
Best sites
Storage
Before reconstitution
Keep the freeze-dried powder frozen at about -20°C and shielded from light until use.
After reconstitution
Once mixed with bacteriostatic water, keep refrigerated at 2–8°C and use within a few weeks.
Signs of degradation — discard the vial
Safety
Is FOXO4-DRI safe?
Side effects
Commonly reported: Temporary tiredness during a cycle
Less common: Injection-site reactions
Stop and seek help if
- Any signs of an allergic reaction (hives, swelling, trouble breathing)
- New or unusual pain, lumps, or unexplained symptoms
- A new cancer diagnosis or cancer treatment starting
- Any reaction at the injection site that worsens
- Simply feeling unwell after use
FOXO4-DRI is a cycled senolytic. Stop a cycle if you feel notably unwell and pick it back up when you recover. If you have a medical condition, loop in a knowledgeable healthcare provider.
Flagged pairings
- Other senolytics (Dasatinib+Quercetin, Fisetin) — Combining multiple zombie-cell-clearing agents at once has not been studied for safety and could add up unpredictably.
- Cancer treatments / chemotherapy — FOXO4-DRI acts on the p53 pathway that cancer therapies also target; combining them is uncharacterized and potentially risky. Oncologist oversight is essential.
- Any prescription medication — No human interaction studies exist. Interactions cannot be ruled out.
- Supplements in general — No interaction data exists. Because human use is experimental, no supplement combination can be called proven safe.
Published research
What the studies show
Baar MP, Brandt RMC, Putavet DA, et al. · 2017
The foundational study. The researchers designed FOXO4-DRI to break the FOXO4–p53 link that keeps senescent cells alive. In mice, it selectively killed senescent cells, neutralized doxorubicin (chemotherapy) toxicity, and restored fitness, fur density, and kidney function in both fast-aging and naturally aged mice.
Huang Y, He Y, Makarcyzk MJ, Lin H. · 2021
In human cartilage cells (chondrocytes) grown and expanded in the lab, 25 micromolar FOXO4-DRI for 5 days cut the share of senescent (aged) cells from over 40% to under 5%, while leaving minimally aged cells unharmed.
Hu et al. · 2025
In blood-vessel lining cells and in mice (5 mg/kg by intraperitoneal injection every 2 days for one month), FOXO4-DRI lowered aging markers (p21, p16, gamma-H2AX), raised BAX and cleaved caspase-3 while lowering BCL-2, restored vessel-cell tube formation and migration, and reduced artery stiffness and inflammation.
Communications Biology (Nature Portfolio) · 2025
In keloid scar cells, FOXO4-DRI triggered death of senescent fibroblasts by pushing phosphorylated p53 (at serine 15) out of the nucleus, supporting a possible role in scar-related research.
Nature Communications · 2025
Using structural biology, researchers showed that both FOXO4 and FOXO4-DRI bind the flexible (disordered) transactivation region of p53 — pinpointing exactly where the peptide acts.
Want the full picture?
The complete FOXO4-DRI research profile: mechanism of action, clinical studies, effectiveness timeline, and FAQ.